|
業務類別
|
Biotechnology |
|
業務概覽
|
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. |
| 公司地址
| 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451 |
| 電話號碼
| +1 510 745-1700 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.ardelyx.com |
| 員工數量
| 489 |
| Dr. Rajani Dinavahi, M.D. |
Chief Medical Officer |
-- |
29/04/2026 |
| Mr. Michael G. Raab |
Director, President and Chief Executive Officer |
美元 797.00K |
29/04/2026 |
| Ms. Susan Hohenleitner |
Chief Financial Officer |
美元 120.93K |
29/04/2026 |
| Mr. Joseph Reilly |
Senior Vice President and Chief Accounting Officer |
-- |
19/02/2026 |
| Dr. John E. Bishop, PhD |
Chief Technical and Quality Officer |
-- |
29/04/2026 |
| Mr. James Parker Brady |
Chief Human Resources Officer |
-- |
29/04/2026 |
| Mr. Eric Duane Foster |
Chief Commercial Officer |
-- |
29/04/2026 |
| Dr. Laura Williams, M.D. |
Chief Patient Officer and Chief Medical Officer |
-- |
29/04/2026 |
| Mr. Michael Kelliher |
Chief Business Officer |
-- |
29/04/2026 |
| Ms. Felecia W. Ettenberg |
Chief Legal Officer |
-- |
29/04/2026 |
|
|
| Mr. Richard J. Rodgers |
Independent Director |
29/04/2026 |
| Dr. Merdad V. Parsey, M.D.,PhD |
Independent Director |
29/04/2026 |
| Mr. William C. Bertrand, Esq.,Jr |
Independent Director |
29/04/2026 |
| Mr. David M. Mott |
Chairman of the Board |
29/04/2026 |
| Dr. Jan M. Lundberg, PhD |
Independent Director |
29/04/2026 |
| Mr. Michael G. Raab |
Director, President and Chief Executive Officer |
29/04/2026 |
| Mr. Robert B. Bazemore, Jr |
Independent Director |
29/04/2026 |
| Ms. Onaiza Cadoret-Manier |
Independent Director |
29/04/2026 |
| Ms. Muna Bhanji, Ph. |
Independent Director |
29/04/2026 |
|
|
|
|
